Cortometrajes de vídeo
Sobrescribir enlaces de ayuda a la navegación
- Inicio
- Cortometrajes De Vídeo
Más popular
Más popular
Popular in Sin nombre
Oncology1m 36s
Enhancing Global Access to Cancer Medicines
Over the last decade we have seen emergence of increasing novel therapies like targeted therapy and immunotherapy & this has changed the natural history of disease for patients living with cancer including those with advanced disease.
biosimilars
access
generics
1
Enhancing Global Access to Cancer Medicines
Myelodysplastic Syndromes3m 14s
Low Risk MDS - Key Practice Points
Myelodysplastic Syndromes (MDS) or Myeloproliferative Neoplasms show considerable heterogeneity with respect to presence of anemia , cytopenia & molecular features.
ipss -m
low risk
molecular features
1
Low Risk MDS - Key Practice Points
Cáncer de mama3m 56s
Duration of trastuzumab in patients with Her2 positive Metastatic Breast Cancer in prolonged remission
There are no randomized clinical trials addressing the continued use of Trastuzumab for Her2 positive MBC patients in prolonged remission and has become important and relevant clinical question.
her2 positive mbc
prolonged remission
trastuzumab duration
1
Duration of trastuzumab in patients with Her2...
Myelodysplastic Syndromes2m 31s
Duration of treatment does it improve outcomes Hypomethylating agents in MD
Need to maximise the response to hypomethylating agents: Standard of care for high-risk Myelodysplastic Syndromes is Hypomethylating agents. Average time to response is about 3 months with either Azacytidine or Decitabine.
duration of treatment
hypomethylating agents
mds
1
Duration of treatment does it improve outcomes...
Myelodysplastic Syndromes2m 25s
Factors that influence treatment adherence and outcomes in MDS
Anticipate & manage adverse events to optimize treatment outcomes: Patients treated with hypomethylating agents are at increased risk of cytopenias & might need support with transfusions.
adverse events
hypomethylating agents
mds
treatment compliance
1
Factors that influence treatment adherence and...
Mieloma múltiple4m 12s
Key Practice Points -Myeloma Related Renal Impairment
In patients with renal impairment primary goal is improvement of Renal Function which is associated with improved treatment outcomes. 50% of patients present renal impairment and renal impairment is severe in 15% of patients.
myeloma
renal impairment
key practice points
1
Key Practice Points -Myeloma Related Renal...
Oncology4m 9s
Cardio Oncology in Prostate Cancer
Major cardiovascular toxicities associated with the prostate cancer treatment include arrhythmias, atherosclerosis, myocardial Infarction, hypertension & cardiomyopathy. Toxicities vary with the type of agent used in Prostate Cancer Treatment.
abcde protocol
cardio oncology
prostate cancer
1
Cardio Oncology in Prostate Cancer
Cancer de prostata4m 19s
Integrating PARP inhibitors in the treatment of Prostate Cancer
Wherever possible all patients with prostate cancer should undergo both germinal and somatic BRCA mutation testing as they represent predictive biomarkers of greater sensitivity to treatment with PARP inhibitors.
profound clinical trial
parp inhibitors
brca mutation
1
Integrating PARP inhibitors in the treatment of...
Mieloma múltiple2m 43s
Practice Points: Management of Infections in Multiple Myeloma
Patients with Multiple Myeloma and plasma cell disorders are at high risk of infections because of compromised immune system. Associated co morbidities can also increase susceptibility to certain infections.
prophylaxis
infections
vaccination
myeloma
1
Practice Points: Management of Infections in...
Oncospecials2m 41s
Low Dose Dasatinib Ready For Clinical Practice
Several studies carried out by institutions of repute have shown that Dasatinib 50 mg is as effective as 100 mg with less side effects.
low dose dasatinib
dasatinib 50mg
1
Low Dose Dasatinib Ready For Clinical Practice
Más reciente
Más reciente
Category Short Cards Listing
Todos los videos
Todos los videos
Iniciar sesión
Por favor inicie sesión para acceder a todo el contenido de MedEnrich
¿Es nuevo/a en MedEnrich? Regístrese ahora